Oxidative stress in drug naïve first episode psychosis and antioxidant effects of risperidone.

[1]  S. Woods,et al.  Antipsychotic‐induced weight gain in first‐episode psychosis patients: a meta‐analysis of differential effects of antipsychotic medications , 2016, Early intervention in psychiatry.

[2]  K. Karakuş,et al.  Paliperidone regulates intracellular redox system in rat brain: Role of purine mechanism , 2015, Redox report : communications in free radical research.

[3]  A. Gadelha,et al.  Effects of depression on the cytokine profile in drug naïve first-episode psychosis , 2015, Schizophrenia Research.

[4]  S. Sinan,et al.  Antidepressant and antipsychotic drugs differentially affect PON1 enzyme activity , 2015, Journal of enzyme inhibition and medicinal chemistry.

[5]  M. Maes,et al.  Effects of Risperidone on Cytokine Profile in Drug-Naïve First-Episode Psychosis , 2015, The international journal of neuropsychopharmacology.

[6]  R. Rosenheck,et al.  Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. , 2014, JAMA psychiatry.

[7]  J. Sato,et al.  Changes in gene expression and methylation in the blood of patients with first-episode psychosis , 2014, Schizophrenia Research.

[8]  A. Stefanović,et al.  Effect of alpha-lipoic acid supplementation on oxidative stress markers and antioxidative defense in patients with schizophrenia. , 2014, Psychiatria Danubina.

[9]  J. Sato,et al.  Evaluation of neurotransmitter receptor gene expression identifies GABA receptor changes: a follow-up study in antipsychotic-naïve patients with first-episode psychosis. , 2014, Journal of psychiatric research.

[10]  Michael Berk,et al.  Oxidative & nitrosative stress in depression: Why so much stress? , 2014, Neuroscience & Biobehavioral Reviews.

[11]  R. Kahn,et al.  The neurobiology and treatment of first-episode schizophrenia , 2014, Molecular Psychiatry.

[12]  M. Najjar,et al.  Paraoxonase 1 activity and lipid profile in schizophrenic patients. , 2014, Asian journal of psychiatry.

[13]  K. Yoo,et al.  Neuroprotection of posttreatment with risperidone, an atypical antipsychotic drug, in rat and gerbil models of ischemic stroke and the maintenance of antioxidants in a gerbil model of ischemic stroke , 2014, Journal of neuroscience research.

[14]  M. Gilca,et al.  A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics , 2014, Psychopharmacology.

[15]  M. Maes,et al.  Neuroprogression in schizophrenia: Pathways underpinning clinical staging and therapeutic corollaries , 2014, The Australian and New Zealand journal of psychiatry.

[16]  N. Barnes,et al.  Cytokine function in medication-naive first episode psychosis: A systematic review and meta-analysis , 2014, Schizophrenia Research.

[17]  K. Hashimoto,et al.  Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine , 2013, Neuropsychiatric disease and treatment.

[18]  A. Pillai,et al.  Antioxidants as potential therapeutics for neuropsychiatric disorders , 2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[19]  M. Maes,et al.  Oxidative stress and lowered total antioxidant status are associated with a history of suicide attempts. , 2013, Journal of affective disorders.

[20]  M. Berk,et al.  Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia , 2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[21]  U. Meyer.  Developmental neuroinflammation and schizophrenia , 2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[22]  S. Dursun,et al.  Nitric oxide plasma/serum levels in patients with schizophrenia: a systematic review and meta-analysis. , 2012, Revista brasileira de psiquiatria.

[23]  J. Moreira,et al.  Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. , 2012, Journal of psychiatric research.

[24]  R. Omdal,et al.  Improved detection of advanced oxidation protein products in plasma. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[25]  A. Cecchini,et al.  Oxidative stress and hematological profiles of advanced breast cancer patients subjected to paclitaxel or doxorubicin chemotherapy , 2012, Breast Cancer Research and Treatment.

[26]  T. Kosten,et al.  Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia , 2012, Neuropharmacology.

[27]  B. Kirkpatrick,et al.  Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects , 2011, Biological Psychiatry.

[28]  B. Dean.  Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies. , 2011, The international journal of neuropsychopharmacology.

[29]  L. Selmeci.  Advanced oxidation protein products (AOPP): novel uremic toxins, or components of the non-enzymatic antioxidant system of the plasma proteome? , 2011, Free radical research.

[30]  M. Berk,et al.  A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[31]  P. Lepping,et al.  Antipsychotic medication and oxidative cell stress: a systematic review. , 2011, The Journal of clinical psychiatry.

[32]  T. Woo,et al.  Oxidative stress in schizophrenia: An integrated approach , 2011, Neuroscience & Biobehavioral Reviews.

[33]  B. Kontek,et al.  Lipid peroxidation in patients with schizophrenia , 2010, Psychiatry and clinical neurosciences.

[34]  Lin He,et al.  A meta-analysis of oxidative stress markers in schizophrenia , 2010, Science China Life Sciences.

[35]  J. Kane,et al.  Definitions of response and remission in schizophrenia: recommendations for their use and their presentation , 2009, Acta psychiatrica Scandinavica. Supplementum.

[36]  B. Olas,et al.  Modifications of blood platelet proteins of patients with schizophrenia , 2009, Platelets.

[37]  G. Jarvik,et al.  Determination of Paraoxonase 1 Status Without the Use of Toxic Organophosphate Substrates , 2008, Circulation. Cardiovascular genetics.

[38]  A. Sarandol,et al.  Coronary artery disease risk factors in patients with schizophrenia: effects of short term antipsychotic treatment , 2007, Journal of psychopharmacology.

[39]  S. Bauer,et al.  The neuropoietic cytokine family in development, plasticity, disease and injury , 2007, Nature Reviews Neuroscience.

[40]  Bernhard Bogerts,et al.  The many faces of nitric oxide in schizophrenia. A review , 2005, Schizophrenia Research.

[41]  D. Horrobin,et al.  Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients , 2003, Biological Psychiatry.

[42]  V. Parikh,et al.  Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics , 2002, Schizophrenia Research.

[43]  W. Fenton,et al.  Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia , 2000, Biological Psychiatry.

[44]  A. Girotti.  Lipid hydroperoxide generation, turnover, and effector action in biological systems. , 1998, Journal of lipid research.

[45]  M. Strauss,et al.  Emotional response as a function of symptoms in schizophrenia , 1998, Schizophrenia Research.

[46]  R. Bressan,et al.  Validity study of the Brazilian version of the Calgary Depression Scale for Schizophrenia , 1998, Schizophrenia Research.

[47]  J. Arenas,et al.  Semiautomated measurement of nitrate in biological fluids. , 1998, Clinical chemistry.

[48]  M. Repetto,et al.  Oxidative stress in blood of HIV infected patients. , 1996, Clinica chimica acta; international journal of clinical chemistry.

[49]  B. Halliwell,et al.  Antioxidants in human health and disease. , 1996, Annual review of nutrition.

[50]  R. S. Smith,et al.  The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. , 1995, Medical hypotheses.

[51]  Jean Addington,et al.  A depression rating scale for schizophrenics , 1990, Schizophrenia Research.

[52]  D. Shih,et al.  Inflammation, infection, cancer and all that…the role of paraoxonases. , 2014, Advances in experimental medicine and biology.

[53]  E. Levy,et al.  The three-gene paraoxonase family: physiologic roles, actions and regulation. , 2011, Atherosclerosis.

[54]  Q. Gong,et al.  Brain anatomical abnormalities in high-risk individuals, first-episode, and chronic schizophrenia: an activation likelihood estimation meta-analysis of illness progression. , 2011, Schizophrenia bulletin.

[55]  V. Parikh,et al.  Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. , 2003, Journal of psychiatric research.

[56]  A. Boveris,et al.  Hydroperoxide-initiated chemiluminescence: an assay for oxidative stress in biopsies of heart, liver, and muscle. , 1991, Free radical biology & medicine.

[57]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.